Erythrityl tetranitrate: sustained effects on systolic time intervals. changes consistent with sustained preload reduction.
The effects of sustained preload reduction have been demonstrated for several nitrates but not for erythrityl titranitrate. In seven patients with coronary heart disease, a randomized double-blind crossover clinical trial showed that chewable erthrityl tetranitrate, 10 mg, produced significant changes in systolic time intervals consistent with preload reduction and lasting for at least four hours. As compared with placebo, ejection time index (ETI) fell and remained significantly low between 6 and 90 minutes after administration, and pre-ejection period (PEP), isovolumic contraction time IVCT),  and pre-ejection period/left ventricular ejection time (PEP/LVET) rose and remained significantly increased between 22 minutes and the four-hour endpoint. We conclude that erythrityl tetranitrate is a physiologically effective long-acting agents in patients with coronary heart disease.
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000503:physiopathology; D004311:Double-Blind Method; D004897:Erythrityl Tetranitrate / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects*; D010919:Placebos; D013599:Systole / Q000187:drug effects*
D010919:Placebos; D004897:Erythrityl Tetranitrate